$HYPR

TEISSEYRE THOMAS sold $10K of HYPR

TEISSEYRE THOMAS (Chief Operating Officer) sold 6,047 shares of Hyperfine, Inc. (HYPR) at $1.65 on 2026-05-26.

Original reporting
SEC EDGAR · TEISSEYRE THOMAS
Published May 27, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HYPR
Bearish
medium confidence
Mentioned
$HYPR
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HYPRBearishMed
01

Why it matters

Traders may reassess near-term sentiment toward HYPR based on officer selling, but there is no accompanying operational, clinical, or financial update.

02

Market read

An officer open-market sale can influence short-term sentiment/positioning, though it is unlikely to drive a major repricing without corroborating news.

03

What to watch

No 10b5-1 plan is cited, but Form 4s can still reflect pre-existing arrangements not captured in the summary; also, one sale does not establish a trend without follow-on filings.

Relevance 7/10Timing: Immediate (filed 2026-05-27; transaction dated 2026-05-26) for short-term sentiment/flow checks.

Background

The article is an SEC Form 4 insider transaction disclosure for Hyperfine, Inc. (HYPR).

Company-level read

Ticker impact

$HYPRBearishMedium confidence
Context

Hyperfine COO TEISSEYRE THOMAS sold 6,047 shares in an open-market transaction for about $9,978, disclosed via SEC Form 4.

Expected impact

Near-term bias to the downside or increased volatility, but likely limited magnitude absent other catalysts.

Evidence & confidence

Form 4 insider sales are common and often non-informational; however, the absence of a stated 10b5-1 plan can raise scrutiny and sentiment sensitivity.

Market effects

Limited read-across; insider sale does not change sector fundamentals for medical technology/diagnostics.

None indicated; US-listed issuer disclosure only.

None indicated; no international transaction or regulatory action mentioned.

Counterpoint

The sale size (~$10k) is small relative to typical insider holdings and may reflect diversification or routine liquidity needs rather than bearish expectations.

Key entities

  • Hyperfine, Inc.

    Subject of the insider sale disclosure; COO TEISSEYRE THOMAS sold 6,047 shares on 2026-05-26.

  • TEISSEYRE THOMAS

    Chief Operating Officer who executed the open-market sale; holdings after transaction: 678,601 shares.

Related articles

$HYPRHigh

Hyperfine, Inc. (HYPR): Results of Operations and Financial Condition

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hypr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imag